The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory metastatic colorectal cancer (mCRC) with wild-type (wt) KRAS status.
D. J. Watkins
No relevant relationships to disclose
J. Tabernero
Consultant or Advisory Role - Merck
H. Schmoll
No relevant relationships to disclose
T. Trarbach
No relevant relationships to disclose
F. J. Ramos
No relevant relationships to disclose
J. Howe
Employment or Leadership Position - Merck
H. M. Brown
Employment or Leadership Position - Merck
J. Clark
Employment or Leadership Position - Merck
K. Hsu
Employment or Leadership Position - Merck
B. D. Lu
Employment or Leadership Position - Merck
D. Cunningham
Research Funding - Amgen; Merck; Merck Serono; Roche